<DOC>
	<DOC>NCT00097552</DOC>
	<brief_summary>This study is a multicenter, open-label, observational, postmarketing surveillance study of Genentech growth hormone (GH) products in the treatment of girls with Turner syndrome in the United States and Canada.</brief_summary>
	<brief_title>A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Are girls with Turner syndrome who are being or will be treated with Nutropin, Nutropin AQ, or Protropin Are willing to keep followup appointments throughout study participation Are girls with Turner syndrome who have submitted Form 4 upon discontinuation and may also submit Form 9 Have Noonan syndrome Subjects treated within the last 6 months with a nonGenentech GH preparation Have closed epiphyses prior to NCGS enrollment Have active neoplasia</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>